Cancer
Malignant Bladder Neoplasm
CI-CAN-00005866Explore in graph →
Top-level346 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005866Explore in graph →
Clinical trials
1,510 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01589094 | Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT02141490 | Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02999672 | A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors(KAMELEON) | completed | Phase 2 | 20 | Hoffmann-La RocheINDUSTRY | 4 | Aug 28, 2019 | clinicaltrials |
| NCT01373294 | Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer | completed | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT02355886 | Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy | completed | Phase 2 / Phase 3 | 25 | University of WashingtonOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT01191892 | Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer | completed | Phase 2 | 82 | Cardiff UniversityOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT00595088 | Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer | completed | Phase 2 | 47 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Apr 30, 2019 | clinicaltrials |
| NCT00526656 | Sunitinib in Treating Patients With Locally Advanced Bladder Cancer | completed | Phase 2 | 9 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02109328 | Alisertib in Chemotherapy-pretreated Urothelial Cancer | completed | Phase 2 | 22 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT00880334 | Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC | completed | Phase 2 | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00578526 | SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial(SPRUCE) | completed | Phase 2 | 64 | AHS Cancer Control AlbertaOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT00310011 | Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium | completed | Phase 2 | 71 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00112671 | Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2018 | clinicaltrials |
| NCT00055601 | Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer | completed | Phase 2 | 97 | Radiation Therapy Oncology GroupNETWORK | 1 | Jun 15, 2018 | clinicaltrials |
| NCT01259063 | RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder | completed | Phase 1 / Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 13, 2018 | clinicaltrials |
| NCT01090466 | Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | completed | Phase 1 / Phase 2 | 15 | Cardiff UniversityOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT00461851 | Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma | completed | Phase 2 | 17 | Yale UniversityOTHER | 1 | Dec 14, 2017 | clinicaltrials |
| NCT00666562 | Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01938573 | Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer | completed | Phase 1 / Phase 2 | 21 | University of WashingtonOTHER | 1 | Oct 20, 2017 | clinicaltrials |
| NCT02655081 | Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy(IMPACT) | completed | Phase 2 | 48 | University of PittsburghOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT01687244 | Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer | completed | Phase 2 | 40 | FKD Therapies OyINDUSTRY | 0 | Jul 24, 2017 | clinicaltrials |
| NCT00380029 | Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 27 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT02307487 | Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients | completed | Phase 2 | 14 | UroGen Pharma Ltd.INDUSTRY | 1 | Jun 16, 2017 | clinicaltrials |
| NCT01108055 | Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer | completed | Phase 2 | 43 | Sandy SrinivasOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT00376987 | Zinc Supplements in Lowering Cadmium Levels in Smokers | completed | Phase 2 | 61 | Wake Forest University Health SciencesOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00534001 | Bupropion in Helping Adults Stop Smoking | completed | Phase 2 | 95 | Roswell Park Cancer InstituteOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01828736 | Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma(CVH-CT02) | completed | Phase 2 | 61 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 2 | Feb 6, 2017 | clinicaltrials |
| NCT00003657 | High-dose ICE With Amifostine | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT00808639 | Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma | completed | Phase 2 | 39 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01454089 | A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer | completed | Phase 2 | 183 | Achieve Life SciencesINDUSTRY | 7 | Oct 7, 2016 | clinicaltrials |
| NCT00588640 | Study of D-Methadone in Patients With Chronic Pain | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT00003565 | Docetaxel in Treating Patients With Solid Tumors | completed | Phase 2 | 109 | Alliance for Clinical Trials in OncologyOTHER | 3 | Jul 14, 2016 | clinicaltrials |
| NCT00645593 | Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer | completed | Phase 2 | 89 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 23, 2016 | clinicaltrials |
| NCT00506155 | Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT00234494 | Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer | completed | Phase 2 | 45 | Christopher Sweeney, MBBSOTHER | 1 | Mar 14, 2016 | clinicaltrials |
| NCT00847015 | Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00587964 | Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00397488 | Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT00234039 | S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin | completed | Phase 2 | 58 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 8, 2016 | clinicaltrials |
| NCT01599013 | JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin(JASINT1) | completed | Phase 2 | 69 | Pierre Fabre MedicamentINDUSTRY | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00389155 | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | completed | Phase 2 / Phase 3 | 34 | Bristol-Myers SquibbINDUSTRY | 16 | Dec 7, 2015 | clinicaltrials |
| NCT00585689 | Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer | completed | Phase 2 | 29 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT01824329 | Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer(SPARC) | completed | Phase 2 | 40 | University of MichiganOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00556621 | Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer(GEMCIRAV) | completed | Phase 1 / Phase 2 | 14 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jul 30, 2015 | clinicaltrials |
| NCT00421889 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | completed | Phase 1 / Phase 2 | 80 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00047216 | Tipifarnib in Treating Patients With Recurrent Bladder Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 2 | Jul 23, 2015 | clinicaltrials |
| NCT00066352 | Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter | completed | Phase 2 | — | University Health Network, TorontoOTHER | 2 | Jul 23, 2015 | clinicaltrials |
| NCT01316874 | Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)(Bladder Cancer) | completed | Phase 2 / Phase 3 | 90 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Jun 12, 2015 | clinicaltrials |
| NCT02007005 | Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 37 | Abnoba GmbhINDUSTRY | 2 | May 6, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Oct 2, 2019source: clinicaltrials